Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

por Nathan W Cummins, Jason Baker, Rana Chakraborty, Patrick G Dean, Enrique Garcia-Rivera, Ashton Krogman, Shaji Kumar, Yury V Kuzmichev, Gregory M Laird, Alan Landay, Mathias Lichterfeld, Maryam Mahmood, Jeffrey Martinson, Mark Maynes, Sekar Natesampillai, Vincent Rajkumar, Yelizaveta Rassadkina, Kristen D. Ritter, Christina G Rivera, Stacey A Rizza, Krupa Subramanian, Aaron J Tande, Elizabeth R Wonderlich, Jennifer A Whitaker, John Zeuli, Andrew D Badley
Publicado 2021